Clinical Trials Logo

Advanced Prostate Cancer clinical trials

View clinical trials related to Advanced Prostate Cancer.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT02035124 Withdrawn - Clinical trials for Advanced Prostate Cancer

Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel

Start date: April 2014
Phase: Phase 2
Study type: Interventional

Although there have been advances in the treatment of patients with metastatic castrate-resistant prostate cancer (mCRPC), all patients eventually develop resistance to available therapy. Docetaxel is the accepted first-line agent followed by cabazitaxel in the post-docetaxel phase. In this study the investigators propose to evaluate BKM120, a PI3K inhibitor, with cabazitaxel in the treatment of patients with advanced prostate cancer.